When evaluating the distribution of immune cell subpopulations per TP53 mutational status, we observed that cell densities of cytotoxic T-cells (at total, tumor and stroma areas), intra-tumoral T-regulatory cells, and stromal macrophages were significantly higher in the TP53-mutated patient subgroup (Fig. 5B–D, Supplementary Table 7). This evidence concerns the gene TP53 and neoplasm.